HER-2 Oncogene and Response to Dose Intensive Therapy

Dressler, Lynn Gail

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: Research Project--Cooperative Agreements (U01)
• Project #: 5U01CA064061-03
• Application #: 2106309
• Study Section: Special Emphasis Panel (SRC (80))
• Project Start: 1994-06-10
• Project End: 1998-03-31
• Budget Start: 1996-08-15
• Budget End: 1997-03-31
• Support Year: 3
• Fiscal Year: 1996

Institution

• Name: University of North Carolina Chapel Hill
• Department: Internal Medicine/Medicine
• Type: Schools of Medicine
• DUNS #: 078861598
• City: Chapel Hill
• State: NC
• Country: United States
• Zip Code: 27599

Publications

DiGiovanna, Michael P; Stern, David F; Edgerton, Susan et al. (2008) Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. J Clin Oncol 26:2364-72

Guidi, Anthony J; Berry, Donald A; Broadwater, Gloria et al. (2002) Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869. J Clin Oncol 20:732-42